MCID: CMB089
MIFTS: 29

Combined Hepatocellular Carcinoma and Cholangiocarcinoma

Categories: Cancer diseases, Liver diseases, Rare diseases

Aliases & Classifications for Combined Hepatocellular Carcinoma and Cholangiocarcinoma

MalaCards integrated aliases for Combined Hepatocellular Carcinoma and Cholangiocarcinoma:

Name: Combined Hepatocellular Carcinoma and Cholangiocarcinoma 58
Combined Hepatocellular-Cholangiocarcinoma 58
Hepatocholangiocarcinoma 58
Combined Hcc-Cc 58
Chcc-Cc 58

Classifications:

Orphanet: 58  
Rare hepatic diseases


External Ids:

Orphanet 58 ORPHA529852

Summaries for Combined Hepatocellular Carcinoma and Cholangiocarcinoma

MalaCards based summary : Combined Hepatocellular Carcinoma and Cholangiocarcinoma, also known as combined hepatocellular-cholangiocarcinoma, is related to hepatoblastoma and cholangiocarcinoma. An important gene associated with Combined Hepatocellular Carcinoma and Cholangiocarcinoma is AKT1 (AKT Serine/Threonine Kinase 1), and among its related pathways/superpathways are p70S6K Signaling and PI3K-Akt signaling pathway. Affiliated tissues include liver, thymus and colon.

Related Diseases for Combined Hepatocellular Carcinoma and Cholangiocarcinoma

Diseases related to Combined Hepatocellular Carcinoma and Cholangiocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 78)
# Related Disease Score Top Affiliating Genes
1 hepatoblastoma 29.5 SALL4 MTOR AKT1
2 cholangiocarcinoma 10.9
3 intrahepatic cholangiocarcinoma 10.9
4 hepatocellular carcinoma 10.8
5 liver cirrhosis 10.4
6 convulsions, familial infantile, with paroxysmal choreoathetosis 10.4
7 liver disease 10.3
8 rare tumor 10.3
9 viral hepatitis 10.2
10 tetralogy of fallot 10.1
11 hepatitis c virus 10.1
12 non-alcoholic steatohepatitis 10.1
13 alcohol dependence 10.1
14 non-alcoholic fatty liver disease 10.1
15 obstructive jaundice 10.1
16 hepatitis c 10.1
17 hepatitis b 10.1
18 mucinous adenocarcinoma 10.1
19 cystadenocarcinoma 10.1
20 tubular adenocarcinoma 10.1
21 cholangiolocellular carcinoma 10.1
22 fatty liver disease 10.1
23 acute sensory ataxic neuropathy 10.1
24 partial third-nerve palsy 10.0 SALL4 AKT1
25 schistosoma mansoni infection, susceptibility/ 10.0
26 budd-chiari syndrome 10.0
27 angiosarcoma 10.0
28 dermatomyositis 10.0
29 portal hypertension 10.0
30 portal vein thrombosis 10.0
31 schistosomiasis 10.0
32 alcoholic liver cirrhosis 10.0
33 angioedema 10.0
34 hepatitis 10.0
35 colon adenocarcinoma 10.0
36 tic disorder 10.0
37 gallbladder cancer 10.0
38 fibrolamellar carcinoma 10.0
39 pulmonary embolism 10.0
40 nodular regenerative hyperplasia 10.0
41 posttransplant acute limbic encephalitis 10.0
42 cholelithiasis 9.9
43 polyneuropathy 9.9
44 squamous cell carcinoma 9.9
45 chronic inflammatory demyelinating polyradiculoneuropathy 9.9
46 demyelinating polyneuropathy 9.9
47 dysphagia 9.9
48 paraneoplastic syndromes 9.9
49 palmoplantar keratoderma, bothnian type 9.8 MTOR AKT1
50 placental choriocarcinoma 9.8 MTOR AKT1

Graphical network of the top 20 diseases related to Combined Hepatocellular Carcinoma and Cholangiocarcinoma:



Diseases related to Combined Hepatocellular Carcinoma and Cholangiocarcinoma

Symptoms & Phenotypes for Combined Hepatocellular Carcinoma and Cholangiocarcinoma

Drugs & Therapeutics for Combined Hepatocellular Carcinoma and Cholangiocarcinoma

Search Clinical Trials , NIH Clinical Center for Combined Hepatocellular Carcinoma and Cholangiocarcinoma

Genetic Tests for Combined Hepatocellular Carcinoma and Cholangiocarcinoma

Anatomical Context for Combined Hepatocellular Carcinoma and Cholangiocarcinoma

MalaCards organs/tissues related to Combined Hepatocellular Carcinoma and Cholangiocarcinoma:

40
Liver, Thymus, Colon, Kidney, Breast, Myeloid

Publications for Combined Hepatocellular Carcinoma and Cholangiocarcinoma

Articles related to Combined Hepatocellular Carcinoma and Cholangiocarcinoma:

(show top 50) (show all 99)
# Title Authors PMID Year
1
Post-resection prognosis of combined hepatocellular carcinoma-cholangiocarcinoma cannot be predicted by the 2019 World Health Organization classification. 61
33766528 2021
2
A rare and distinct hepatic tumor: Hepatocholangiocarcinoma. 61
33768957 2021
3
New insights into the pathophysiology and clinical care of rare primary liver cancers. 61
33205035 2021
4
The clinical characteristics and prognostic factors of combined Hepatocellular Carcinoma and Cholangiocarcinoma, Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma after Surgical Resection: A propensity score matching analysis. 61
33390787 2021
5
Clinical features and outcomes of combined hepatocellular carcinoma and cholangiocarcinoma versus hepatocellular carcinoma versus cholangiocarcinoma after surgical resection: a propensity score matching analysis. 61
33413162 2021
6
Totally robotic caudate lobe liver resection: Bridge over troubled water. 61
32931627 2020
7
Is the outcome after hepatectomy for transitional hepatocholangiocarcinoma different from that of hepatocellular carcinoma and mass-forming cholangiocarcinoma? A case-matched analysis. 61
32445033 2020
8
Adjuvant Transarterial chemoembolization does not influence recurrence-free or overall survival in patients with combined hepatocellular carcinoma and Cholangiocarcinoma after curative resection: a propensity score matching analysis. 61
32650743 2020
9
Activation of the Akt/mammalian target of rapamycin pathway in combined hepatocellular carcinoma and cholangiocarcinoma: significant correlation between p-4E-BP1 expression in cholangiocarcinoma component and prognosis. 61
31927624 2020
10
Long-term outcome and prognostic factors of combined hepatocellular carcinoma and cholangiocarcinoma after curative resection. 61
32280473 2020
11
Risk Factors of Tumor Recurrence After Liver Transplantation for Combined Hepatocellular Carcinoma and Cholangiocarcinoma. 61
31926744 2020
12
The distribution of immune cells within combined hepatocellular carcinoma and cholangiocarcinoma predicts clinical outcome. 61
32508015 2020
13
Surgical Treatment of Hepatocholangiocarcinoma: A Systematic Review. 61
32071906 2020
14
Prolonged efficacy of pembrolizumab in a patient presenting a multi-treated metastatic hepatocholangiocarcinoma. 61
32612680 2020
15
Comparison of Imaging and Clinically Relevant Features of Combined Hepatocellular Carcinoma and Cholangiocarcinoma with Hepatocellular Carcinoma. 61
31726461 2019
16
Imaging features of combined hepatocellular and cholangiocarcinoma compared with those of hepatocellular carcinoma and intrahepatic cholangiocellular carcinoma in a Chinese population. 61
30799097 2019
17
Combined Hepatocholangiocarcinoma Associated with Humoral Hypercalcemia of Malignancy and Chronic Inflammatory Demyelinating Polyneuropathy. 61
31341687 2019
18
Comparing Clonality Between Components of Combined Hepatocellular Carcinoma and Cholangiocarcinoma by Targeted Sequencing. 61
29976634 2018
19
Rapidly progressing lepidic pulmonary metastases from a treated poorly differentiated hepatocellular carcinoma demonstrating new pathologic features of cholangiocarcinoma: A potential diagnostic pitfall that may mimic pneumonia. 61
29904468 2018
20
Hepatocholangiocarcinoma/intrahepatic cholangiocarcinoma: are they contraindication or indication for liver transplantation? A propensity score-matched analysis. 61
29450868 2018
21
Esophageal metastasis of stem cell-subtype hepatocholangiocarcinoma: Rare presentation of a rare tumor. 61
29467557 2018
22
Gemcitabine plus platinum-based chemotherapy for first-line treatment of hepatocholangiocarcinoma: an AGEO French multicentre retrospective study. 61
29169182 2018
23
Retinal and vitreous metastases from hepatocholangiocarcinoma. 61
28629380 2017
24
Importance of surgical margin in the outcomes of hepatocholangiocarcinoma. 61
28539991 2017
25
[Hepatocholangiocarcinoma in young patient with a giant liver tumour]. 61
27012432 2017
26
Post-resection Prognosis of Combined Hepatocellular Carcinoma-Cholangiocarcinoma According to the 2010 WHO Classification. 61
27896409 2017
27
Living Donor Liver Transplantation for Combined Hepatocellular Carcinoma and Cholangiocarcinoma: Experience of a Single Center. 61
28242867 2017
28
Mutational landscape of combined hepatocellular carcinoma and cholangiocarcinoma, and its clinicopathological significance. 61
27634656 2017
29
Tumor specific mutations in TERT promoter and CTNNB1 gene in hepatitis B and hepatitis C related hepatocellular carcinoma. 61
27276713 2016
30
Imaging Features of Biphenotypic Primary Liver Carcinoma (Hepatocholangiocarcinoma) and the Potential to Mimic Hepatocellular Carcinoma: LI-RADS Analysis of CT and MRI Features in 61 Cases. 61
26866746 2016
31
Combined Hepatocellular Carcinoma and Cholangiocarcinoma: Diagnosis and Prognosis After Resection or Transplantation. 61
27320566 2016
32
Spalt-like transcription factor 4 immunopositivity is associated with epithelial cell adhesion molecule expression in combined hepatocellular carcinoma and cholangiocarcinoma. 61
26267070 2016
33
Incidental Intra-Hepatic Cholangiocarcinoma and Hepatocholangiocarcinoma in Liver Transplantation: A Single-Center Experience. 61
27109957 2016
34
Combined hepatocellular carcinoma and cholangiocarcinoma (biphenotypic) tumors: clinical characteristics, imaging features of contrast-enhanced ultrasound and computed tomography. 61
26917546 2016
35
Postresection Outcomes of Combined Hepatocellular Carcinoma-Cholangiocarcinoma, Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. 61
26628072 2016
36
Osteopontin Promotes Hepatic Progenitor Cell Expansion and Tumorigenicity via Activation of β-Catenin in Mice. 61
26033745 2015
37
A case of hepatoblastoma misdiagnosed as combined hepatocellular carcinoma and cholangiocarcinoma in an adult. 61
26523273 2015
38
Intrahepatic cholangiocarcinoma: expert consensus statement. 61
26172134 2015
39
Clinicopathological features and prognosis of combined hepatocellular carcinoma and cholangiocarcinoma after surgery. 61
25475861 2014
40
GEMOX as the best hope for combined hepatocellular carcinoma and cholangiocarcinoma? 61
25327932 2014
41
Inverse correlation of ribosomal protein S27A and multifunctional protein YB-1 in hepatocellular carcinoma. 61
24833360 2014
42
Combined hepatocellular-cholangiocarcinoma with fever of unknown origin: a case report and review of literature. 61
24068520 2014
43
Species and gender differences in the carcinogenic activity of trimethylolpropane triacrylate in rats and mice. 61
24503412 2014
44
[Clinical characteristics and prognosis of three rare and poor-prognostic subtypes of primary liver carcinoma]. 61
24785282 2014
45
Elevated expression of Bmi1 in hepatocellular carcinoma with bile duct tumor thrombi. 61
24719948 2013
46
Clinicopathological characteristics and prognostic factors in combined hepatocellular carcinoma and cholangiocarcinoma. 61
26155231 2013
47
Long-term outcome of liver transplantation for combined hepatocellular carcinoma and cholangiocarcinoma. 61
24157031 2013
48
Gallbladder metastatic combined hepatocellular carcinoma and cholangiocarcinoma without primary intrahepatic tumor. 61
23703449 2013
49
Clinicopathological factors impact the survival outcome following the resection of combined hepatocellular carcinoma and cholangiocarcinoma. 61
23102615 2013
50
Exophytic combined hepatocellular carcinoma and cholangiocarcinoma. 61
23323259 2012

Variations for Combined Hepatocellular Carcinoma and Cholangiocarcinoma

Expression for Combined Hepatocellular Carcinoma and Cholangiocarcinoma

Search GEO for disease gene expression data for Combined Hepatocellular Carcinoma and Cholangiocarcinoma.

Pathways for Combined Hepatocellular Carcinoma and Cholangiocarcinoma

Pathways related to Combined Hepatocellular Carcinoma and Cholangiocarcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 69)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.79 MTOR EIF4EBP1 AKT1
2
Show member pathways
12.73 MTOR EIF4EBP1 AKT1
3
Show member pathways
12.69 MTOR EIF4EBP1 AKT1
4
Show member pathways
12.59 MTOR EIF4EBP1 AKT1
5
Show member pathways
12.55 MTOR EIF4EBP1 AKT1
6 12.55 MTOR EIF4EBP1 AKT1
7
Show member pathways
12.47 MTOR EIF4EBP1 AKT1
8
Show member pathways
12.29 MTOR EIF4EBP1 AKT1
9
Show member pathways
12.27 MTOR EIF4EBP1 AKT1
10
Show member pathways
12.26 MTOR EIF4EBP1 AKT1
11
Show member pathways
12.25 MTOR EIF4EBP1 AKT1
12
Show member pathways
12.24 MTOR EIF4EBP1 AKT1
13
Show member pathways
12.22 MTOR EIF4EBP1 AKT1
14
Show member pathways
12.16 MTOR EIF4EBP1 AKT1
15
Show member pathways
12.14 MTOR EIF4EBP1 AKT1
16
Show member pathways
12.13 MTOR EIF4EBP1 AKT1
17
Show member pathways
12.05 MTOR EIF4EBP1 AKT1
18
Show member pathways
12.03 MTOR AKT1
19
Show member pathways
11.99 MTOR EIF4EBP1 AKT1
20
Show member pathways
11.96 MTOR EIF4EBP1 AKT1
21 11.93 MTOR EIF4EBP1 AKT1
22
Show member pathways
11.91 MTOR EIF4EBP1 AKT1
23 11.9 MTOR AKT1
24 11.88 MTOR AKT1
25 11.88 MTOR AKT1
26 11.88 MTOR EIF4EBP1 AKT1
27
Show member pathways
11.83 MTOR EIF4EBP1 AKT1
28
Show member pathways
11.82 MTOR EIF4EBP1
29 11.82 MTOR AKT1
30 11.79 MTOR EIF4EBP1 AKT1
31 11.78 MTOR AKT1
32
Show member pathways
11.78 MTOR EIF4EBP1 AKT1
33
Show member pathways
11.77 MTOR AKT1
34 11.74 MTOR AKT1
35
Show member pathways
11.71 MTOR AKT1
36 11.71 MTOR AKT1
37 11.68 MTOR EIF4EBP1
38
Show member pathways
11.67 MTOR AKT1
39 11.65 MTOR AKT1
40
Show member pathways
11.65 MTOR AKT1
41 11.65 MTOR EIF4EBP1 AKT1
42 11.59 MTOR AKT1
43 11.57 MTOR AKT1
44
Show member pathways
11.57 MTOR AKT1
45 11.56 MTOR AKT1
46 11.55 MTOR AKT1
47 11.55 MTOR AKT1
48 11.54 MTOR AKT1
49 11.53 MTOR AKT1
50
Show member pathways
11.52 MTOR AKT1

GO Terms for Combined Hepatocellular Carcinoma and Cholangiocarcinoma

Cellular components related to Combined Hepatocellular Carcinoma and Cholangiocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 postsynaptic cytosol GO:0099524 8.96 MTOR EIF4EBP1
2 protein-containing complex GO:0032991 8.92 SALL4 MTOR EIF4EBP1 AKT1

Biological processes related to Combined Hepatocellular Carcinoma and Cholangiocarcinoma according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of endothelial cell proliferation GO:0001938 9.58 MTOR AKT1
2 peptidyl-threonine phosphorylation GO:0018107 9.57 MTOR AKT1
3 positive regulation of smooth muscle cell proliferation GO:0048661 9.56 MTOR AKT1
4 negative regulation of protein ubiquitination GO:0031397 9.55 MTOR AKT1
5 negative regulation of autophagy GO:0010507 9.54 MTOR AKT1
6 positive regulation of nitric oxide biosynthetic process GO:0045429 9.52 MTOR AKT1
7 protein catabolic process GO:0030163 9.51 MTOR AKT1
8 germ cell development GO:0007281 9.49 MTOR AKT1
9 activation of protein kinase B activity GO:0032148 9.48 MTOR AKT1
10 spinal cord development GO:0021510 9.46 MTOR AKT1
11 regulation of myelination GO:0031641 9.43 MTOR AKT1
12 positive regulation of lipid biosynthetic process GO:0046889 9.4 MTOR AKT1
13 negative regulation of macroautophagy GO:0016242 9.37 MTOR AKT1
14 regulation of glycogen biosynthetic process GO:0005979 9.32 MTOR AKT1
15 anoikis GO:0043276 9.26 MTOR AKT1
16 negative regulation of cell size GO:0045792 9.16 MTOR AKT1
17 cellular response to hypoxia GO:0071456 9.13 MTOR EIF4EBP1 AKT1
18 TOR signaling GO:0031929 8.8 MTOR EIF4EBP1 AKT1

Molecular functions related to Combined Hepatocellular Carcinoma and Cholangiocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein phosphatase 2A binding GO:0051721 8.62 EIF4EBP1 AKT1

Sources for Combined Hepatocellular Carcinoma and Cholangiocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....